Francesca Romana Mauro

List of Publications by Year
in descending order

176 papers	5,395 citations	109321 35 h-index	95266 68 g-index
176 all docs	176 docs citations	176 times ranked	5615 citing authors

#	Article	IF	Citations
1	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 2007, 109, 4944-4951.	1.4	471
2	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	1.4	420
3	Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 2000, 95, 2786-2792.	1.4	261
4	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2008, 142, 202-215.	2.5	206
5	Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases. Blood, 1999, 94, 448-454.	1.4	203
6	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	7.2	198
7	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
8	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood, 1998, 91, 4342-4349.	1.4	176
9	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood, 2008, 112, 782-792.	1.4	121
10	Familial Cancer Associated with a Polymorphism in<i>ARLTS1</i>. New England Journal of Medicine, 2005, 352, 1667-1676.	27.0	119
11	Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	4.1	104
12	ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica, 2012, 97, 47-55.	3.5	92
13	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
14	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood, 2007, 110, 3326-3333.	1.4	79
15	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood, 2014, 123, 2378-2388.	1.4	78
16	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood, 2003, 102, 1035-1041.	1.4	74
17	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemia–Susceptibility Loci. American Journal of Human Genetics, 2005, 77, 420-429.	6.2	65
18	Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood, 2009, 114, 638-646.	1.4	65

#	Article	IF	Citations
19	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	8.5	65
20	Biological and clinical implications of *BIRC3* mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
21	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia, 2021, 35, 737-746.	7.2	61
22	Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica, 2006, 91, 1689-92.	3.5	61
23	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2019, 104, 2053-2060.	3.5	60
24	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
25	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	1.7	55
26	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood, 2016, 128, 2093-2095.	1.4	52
27	The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. British Journal of Haematology, 2005, 130, 549-557.	2.5	51
28	Histopathological and molecular features of persistent polyclonal B‐cell lymphocytosis (PPBL) with progressive splenomegaly. British Journal of Haematology, 2009, 144, 726-731.	2.5	51
29	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica, 2011, 96, 277-283.	3.5	47
30	The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience. American Journal of Hematology, 2011, 86, 1007-1012.	4.1	47
31	*NOTCH1, SF3B1, BIRC3* and *TP53* mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. Leukemia and Lymphoma, 2014, 55, 2785-2792.	1.3	47
32	V$_H$ gene usage by family members affected with chronic lymphocytic leukaemia. British Journal of Haematology, 1999, 107, 616-624.	2.5	45
33	Hodgkin / Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 129-132.	2.8	42
34	HIF-1α is over-expressed in leukemic cells from *TP53*-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
35	Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. Haematologica, 2021, 106, 622-625.	3.5	39
36	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica, 2010, 95, 464-469.	3.5	37

#	Article	IF	Citations
37	B‑cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 32-36.	4.1	36
38	Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica, 2006, 91, 1117-20.	3.5	35
39	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 2018, 181, 229-233.	2.5	34
40	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood, 2020, 136, 763-766.	1.4	33
41	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood, 2020, 135, 1244-1254.	1.4	33
42	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 2019, 121, 150-156.	6.4	31
43	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	3.5	31
44	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood, 2008, 111, 5691-5693.	1.4	30
45	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
46	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood, 2021, 137, 3507-3517.	1.4	30
47	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leukemia Research, 2015, 39, 1066-1070.	0.8	29
48	Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19+ cells in vivo and in vitro. British Journal of Haematology, 2004, 125, 720-728.	2.5	27
49	White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica, 2011, 96, 626-630.	3.5	27
50	Chromosome 2p gain in monoclonal B‑cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
51	Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ‑PCR. British Journal of Haematology, 2014, 166, 360-368.	2.5	27
52	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 113, 391-399.	2.5	26
53	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR‑132 and miR‑212. Genes Chromosomes and Cancer, 2015, 54, 222-234.	2.8	26
54	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. Genes Chromosomes and Cancer, 2011, 50, 263-274.	2.8	25

#	Article	IF	Citations
55	Italian external and multicentric validation of the <scp>MD A</scp>nderson <scp>C</scp>ancer <scp>C</scp>enter nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. British Journal of Haematology, 2014, 167, 224-232.	2.5	25
56	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. European Journal of Cancer, 2016, 60, 154-165.	2.8	22
57	New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Current Opinion in Oncology, 2005, 17, 597-604.	2.4	21
58	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2005, 46, 553-560.	1.3	21
59	Behind the scenes of non‐nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, <i>TP53</i> pathway and mutated status of immunoglobulin heavy chain genes. British Journal of Haematology, 2012, 156, 601-611.	2.5	21
60	Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. Blood, 2009, 114, 2848-2849.	1.4	20
61	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B‐cell receptor structure, function, and patients' prognosis. American Journal of Hematology, 2014, 89, 74-82.	4.1	20
62	Inter‐and intra‐patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. British Journal of Haematology, 2016, 172, 371-383.	2.5	20
63	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. American Journal of Hematology, 2017, 92, 529-535.	4.1	20
64	Chronic lymphocytic leukemia in less fit patients: "slow-go". Leukemia and Lymphoma, 2011, 52, 2207-2216.	1.3	18
65	Comparison between the CLL‐IPI and the <scp>B</scp>arcelona‐<scp>B</scp>rno prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 2018, 93, E35-E37.	4.1	18
66	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. British Journal of Haematology, 2020, 189, 853-859.	2.5	18
67	An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2012, 156, 481-489.	2.5	17
68	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research, 2017, 57, 65-71.	0.8	17
69	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	7.2	17
70	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 637186.	2.8	17
71	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. Blood, 2010, 116, 2462-2462.	1.4	17
72	Enteral nutrition may cause false-positive results of Aspergillus Galactomannan assay in absence of gastrointestinal diseases. Mycoses, 2011, 54, e883-e884.	4.0	16

#	Article	IF	Citations
73	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers, 2019, 11, 896.	3.7	16
74	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. Leukemia Research, 2019, 87, 106233.	0.8	16
75	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 2021, 13, 3240.	3.7	16
76	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. Experimental Hematology, 2012, 40, 197-206.e1.	0.4	15
77	Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. Haematologica, 2013, 98, 371-375.	3.5	15
78	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	4.1	15
79	Standard conditioning regimen and t-depleted donor bone marrow for transplantation in chronic myeloid leukemia. Leukemia Research, 1986, 10, 1469-1475.	0.8	14
80	Late listeriosis after fludarabine plus prednisone treatment. British Journal of Haematology, 1994, 87, 407-408.	2.5	14
81	Venetoclax in CLL patients who progress after B‐cell Receptor inhibitor treatment: a retrospective multi‐centre Italian experience. British Journal of Haematology, 2019, 187, e8-e11.	2.5	14
82	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	5.2	14
83	Continuous treatment with Ibrutinib in 100 untreated patients with *TP*53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study. American Journal of Hematology, 2022, 97, .	4.1	14
84	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 2014, 38, 1269-1277.	0.8	13
85	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
86	Bullous lesions in chronic lymphocytic leukaemia: pemphigoid or insect bites?. Acta Dermato-Venereologica, 2006, 86, 74-76.	1.3	13
87	Monocytopenia and infections in chronic lymphocytic leukemia (CLL). European Journal of Haematology, 1991, 46, 119-119.	2.2	12
88	Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leukemia Research, 2010, 34, 733-741.	0.8	12
89	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
90	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. American Journal of Hematology, 2020, 95, 604-611.	4.1	12

#	Article	IF	Citations
91	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. Haematologica, 2022, 107, 1470-1473.	3.5	12
92	Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. Leukemia and Lymphoma, 2012, 53, 1660-1665.	1.3	10
93	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
94	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. Leukemia and Lymphoma, 2016, 57, 2429-2431.	1.3	10
95	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2018, 11, 601-611.	2.2	10
96	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
97	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica, 2017, 102, e352-e355.	3.5	9
98	Clinical relevance of silent red blood cell autoantibodies. Haematologica, 2017, 102, e473-e475.	3.5	9
99	Biallelic *BIRC3* inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. British Journal of Haematology, 2019, 185, 156-159.	2.5	9
100	Unravelling the suboptimal response of *TP53*â€mutated chronic lymphocytic leukaemia to ibrutinib. British Journal of Haematology, 2019, 184, 392-396.	2.5	9
101	Management of chronic lymphocytic leukemia in Italy during a one year of the COVIDâ€19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematological Oncology, 2021, 39, 570-574.	1.7	9
102	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood, 2021, 138, 2727-2730.	1.4	9
103	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase Iâ€"II GIMEMA trial. Leukemia and Lymphoma, 2017, 58, 1640-1647.	1.3	8
104	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
105	Predictive value of the CLLâ€IPI in CLL patients receiving chemoâ€immunotherapy as firstâ€line treatment. European Journal of Haematology, 2018, 101, 703-706.	2.2	8
106	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	1.7	8
107	*TP53* disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
108	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research, 2012, 36, 459-466.	0.8	7

#	Article	IF	Citations
109	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. Leukemia Research, 2013, 37, 455-462.	0.8	7
110	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O‐CLL1‐GISL study. European Journal of Haematology, 2016, 96, 36-45.	2.2	7
111	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
112	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. Haematologica, 2021, 106, 1500-1503.	3.5	7
113	Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	2.5	7
114	Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1165-1175.	2.2	6
115	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	2.8	6
116	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. Blood, 2018, 132, 3118-3118.	1.4	6
117	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. Blood, 2011, 118, 294-294.	1.4	6
118	Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient. Journal of Clinical Virology, 2011, 52, 247-250.	3.1	5
119	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. Frontiers in Oncology, 2020, 10, 848.	2.8	5
120	Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
121	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model. American Journal of Hematology, 2022, 97, .	4.1	5
122	Is the Aberrant Expression of p53 by Immunocytochemistry a Surrogate Marker of *TP53* Mutation and/or Deletion in Chronic Lymphocytic Leukemia?. American Journal of Clinical Pathology, 2011, 135, 173-174.	0.7	4
123	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 2014, 38, 198-203.	0.8	4
124	A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for *IGHV‐D‐J* rearrangements and *BRAF* V600E mutation: lack of evidence for a common origin. British Journal of Haematology, 2016, 174, 329-331.	2.5	4
125	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers, 2020, 12, 1773.	3.7	4
126	Treatment with ibrutinib does not induce a *TP53* clonal evolution in chronic lymphocytic leukemia. Haematologica, 2022, 107, 334-337.	3.5	4

#	Article	IF	Citations
127	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. Hematological Oncology, 2022, 40, 518-527.	1.7	4
128	5â€²-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leukemia Research, 2011, 35, 1409-1411.	0.8	3
129	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. Hematological Oncology, 2021, 39, 141-144.	1.7	3
130	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
131	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. Blood, 2018, 132, 4954-4954.	1.4	3
132	Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. Blood, 2015, 126, 3305-3305.	1.4	3
133	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	1.4	3
134	BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion. Blood, 2014, 124, 3295-3295.	1.4	3
135	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. Blood, 2020, 136, 25-26.	1.4	3
136	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. Hematological Oncology, 2022, 40, 332-340.	1.7	3
137	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, , 1-4.	1.3	3
138	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	3.7	3
139	Gene mutations in lenalidomide-treated CLL. Blood, 2018, 131, 1769-1771.	1.4	2
140	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 4412-4412.	1.4	2
141	Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. Blood, 2019, 134, 3516-3516.	1.4	2
142	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	1.4	2
143	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. Blood, 2012, 120, 1784-1784.	1.4	2
144	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. Blood, 2010, 116, 1360-1360.	1.4	2

#	Article	IF	Citations
145	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
146	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. Blood, 2020, 136, 54-55.	1.4	2
147	Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. Lancet Oncology, The, 2017, 18, 270-271.	10.7	1
148	Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Chemotherapy, 2017, 62, 350-352.	1.6	1
149	Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. Lancet Oncology, The, 2018, 19, 7-8.	10.7	1
150	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica, 2020, 105, 2671-2674.	3.5	1
151	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. Blood, 2018, 132, 1834-1834.	1.4	1
152	The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVH Mutated and Unmutated Patients.. Blood, 2006, 108, 298-298.	1.4	1
153	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. Blood, 2015, 126, 2946-2946.	1.4	1
154	IgVH Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.. Blood, 2007, 110, 1133-1133.	1.4	1
155	Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study. Blood, 2010, 116, 1377-1377.	1.4	1
156	TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Blood, 2018, 132, 3119-3119.	1.4	1
157	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	1.4	1
158	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood, 2020, 136, 33-34.	1.4	1
159	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. Clinical and Experimental Rheumatology, 2021, 39, 838-843.	0.8	1
160	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic workâ€up. American Journal of Hematology, 2016, 91, E319-20.	4.1	0
161	Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.. Blood, 2004, 104, 1922-1922.	1.4	0
162	Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.. Blood, 2006, 108, 2794-2794.	1.4	0

#	Article	IF	Citations
163	Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. Blood, 2006, 108, 4612-4612.	1.4	0
164	Chronic Lymphocytic Leukemia (CLL) with Discordance in ZAP-70 Expression and IgVH Mutation Status.. Blood, 2006, 108, 2787-2787.	1.4	0
165	Angiogenic Activity in IgVH Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.. Blood, 2006, 108, 2819-2819.	1.4	0
166	A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors. Blood, 2008, 112, 3121-3121.	1.4	0
167	ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression.. Blood, 2008, 112, 2084-2084.	1.4	0
168	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1780-1780.	1.4	0
169	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2930-2930.	1.4	0
170	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	1.4	0
171	HIF-1Î± Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	1.4	0
172	Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. Blood, 2018, 132, 5550-5550.	1.4	0
173	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 1844-1844.	1.4	0
174	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. Blood, 2020, 136, 23-25.	1.4	0
175	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	0
176	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent Bâ€cell lymphomas. Hematological Oncology, 2023, 41, 571-573.	1.7	0